*Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, China; †Special Department of Hemangioma, Hospital of PLA General Political Department, Beijing, China.
Dermatol Surg. 2014 Aug;40(8):899-905. doi: 10.1111/dsu.0000000000000061.
Lymphangioma circumscriptum (LC) is a type of microcystic lymphatic malformation involving the skin and mucosa that presents as translucent vesicles of varying size with a pink, red, or black hue. Lymphangioma circumscriptum causes not only cosmetic problems but also refractory rupture, infection, lymphorrhea, and bleeding. Various invasive methods, such as surgical excision, lasers, and sclerotherapy, have been used in the past to treat LC with varying success. Herein, we report a new treatment for the management of LC.
This study reports the outcomes of 12 patients (aged 4-31 years) with LC treated by electrocoagulation using a special isolated needle. Patient demographics, lesion characteristics, radiologic findings, treatment course, and clinical responses are recorded.
All 12 patients who were treated with the highly selective electrocoagulation therapy achieved near-complete clearance. Minimal intra- and postoperative sequelae were observed. The local complications included mild pain (n = 9), proliferous scarring (n = 1), and ulceration (n = 1) with no systemic side effects. The mean follow-up period was 8.25 months (3-14 months).
Highly selective electrocoagulation therapy is an innovative, minimally invasive technique that seems to be safe and effective for the treatment of LC; the results from our limited study population seem promising, and the observed complications are acceptable.
淋巴管瘤（LC）是一种涉及皮肤和黏膜的微囊型淋巴畸形，表现为大小不一的半透明囊泡，呈粉红色、红色或黑色。淋巴管瘤不仅会造成美容问题，还会导致难治性破裂、感染、淋巴液外渗和出血。过去，各种有创方法，如手术切除、激光和硬化治疗，已被用于治疗 LC，但疗效不一。在此，我们报告一种新的治疗 LC 的方法。
本研究报告了 12 例（年龄 4-31 岁）LC 患者采用特殊的隔离针进行电凝治疗的结果。记录患者的人口统计学资料、病变特征、影像学表现、治疗过程和临床反应。
所有接受高度选择性电凝治疗的 12 例患者均获得近乎完全清除。观察到轻微的术中及术后后遗症。局部并发症包括轻度疼痛（9 例）、增殖性瘢痕（1 例）和溃疡（1 例），无全身副作用。平均随访时间为 8.25 个月（3-14 个月）。
高度选择性电凝治疗是一种创新的微创技术，似乎对 LC 的治疗安全且有效；我们的有限研究人群的结果很有前景，观察到的并发症是可以接受的。
